Christopher J Rankin, Age 43535 Wilson Pl, Frederick, MD 21702

Christopher Rankin Phones & Addresses

535 Wilson Pl, Frederick, MD 21702 (301) 662-4456

Rockville, MD

Tampa, FL

Charlotte, NC

Wilmington, NC

Columbia, SC

Elgin, SC

Boyds, MD

Show more

Work

Company: Freightliner - Cleveland, NC Mar 2012 Position: Pdi tech 1

Education

School / High School: University of North Carolina at Charlotte- Charlotte, NC May 2014 Specialities: BS in Political Science

Mentions for Christopher J Rankin

Professional Records

Medicine Doctors

Christopher C. Rankin

Specialties:
Orthopaedic Surgery, Orthopedic Sports Medicine
Work:
The Doctors ClinicDoctors Clinic Orthopedics & Sports Medicine
2200 NW Myhre Rd STE 301, Silverdale, WA 98383
(360) 830-1322 (phone) (360) 830-1385 (fax)
Site
Education:
Medical School
Baylor College of Medicine
Graduated: 1995
Procedures:
Hallux Valgus Repair, Shoulder Surgery, Arthrocentesis, Carpal Tunnel Decompression, Hip/Femur Fractures and Dislocations, Joint Arthroscopy, Knee Arthroscopy, Knee Replacement, Lower Arm/Elbow/Wrist Fractures and Dislocations, Lower Leg/Ankle Fractures and Dislocations, Shoulder Arthroscopy
Conditions:
Fractures, Dislocations, Derangement, and Sprains, Internal Derangement of Knee, Internal Derangement of Knee Cartilage, Internal Derangement of Knee Ligaments, Intervertebral Disc Degeneration, Lateral Epicondylitis, Osteoarthritis, Osteomyelitis, Plantar Fascitis, Rheumatoid Arthritis, Rotator Cuff Syndrome and Allied Disorders, Sciatica, Spinal Stenosis
Languages:
English, Spanish
Description:
Dr. Rankin graduated from the Baylor College of Medicine in 1995. He works in Silverdale, WA and specializes in Orthopaedic Surgery and Orthopedic Sports Medicine. Dr. Rankin is affiliated with Harrison Medical Center.

Christopher D. Rankin

Specialties:
Internal Medicine
Work:
Meadowlands Hospital Medical Center Internal Medicine Residency
55 Meadowlands Pkwy, Secaucus, NJ 07094
(201) 392-3100 (phone) (201) 392-3527 (fax)
Languages:
English
Description:
Dr. Rankin works in Secaucus, NJ and specializes in Internal Medicine.

License Records

Christopher J. Rankin

Licenses:
License #: RN1006859 - Expired
Category: NURSING
Issued Date: 8, 2005
Expiration Date: 6, 2010
Type: REGISTERED NURSE

Resumes

Resumes

Christopher Rankin Photo 1

Service Delivery Manager At Cgi

Position:
Service Delivery Manager at CGI
Location:
Washington D.C. Metro Area
Industry:
Information Technology and Services
Work:
CGI - Fairfax, VA since Aug 2012
Service Delivery Manager
Deloitte Consulting LLP - Arlington, VA May 2007 - Aug 2012
Manager
Booz Allen Hamilton - McLean, VA Mar 2002 - May 2007
Senior Consultant
Self - Employed Jan 2002 - Mar 2002
Software Development Expert
National Rifle Association Oct 2000 - Jan 2002
Systems Analyst
Booz Allen Hamilton Mar 2000 - Oct 2000
Consultant
American Management Systems (AMS) Jul 1998 - Mar 2000
Consultant
Levin Consulting Jan 1997 - Dec 1997
Intern
Education:
John Carroll University 1993 - 1998
BS, Economics
Skills:
SharePoint, SDLC, Functional Requirements, Web Application Design, Project Management, Data Visualization, Microsoft Office, SQL, Databases, Analytics, Visualization Software, Technical Requirements, Database Design, Database-driven Web Applications, Information Visualization, Spotfire, Web Architecture, Oral Communication, Toad, Oracle Application Express, Staff Supervision, Presentations, Client Presentation, Creativity, Written Communication, PowerBuilder
Interests:
Photography, remote control models, HO scale trains, boating
Christopher Rankin Photo 2

Christopher Rankin - Mount Ulla, NC

Work:
Freightliner - Cleveland, NC Mar 2012 to Jan 2014
PDI Tech 1
ESC - Troutman, NC Jan 2012 to Mar 2012
Machine Operator
Cookout - Mooresville, NC Jun 2005 to Aug 2007
Crew Leader
Education:
University of North Carolina at Charlotte - Charlotte, NC May 2014
BS in Political Science
West Rowan High School Jun 2007
High School Diploma in Partial Academic
Christopher Rankin Photo 3

Christopher Rankin

Location:
Whitefish, Montana
Industry:
Information Technology and Services
Skills:
Sales Management, Account Management, Selling, Pricing, SaaS, E-commerce, Business Development, Sales, New Business Development, Direct Sales, Salesforce.com, Enterprise Solution Sales, Sales Presentations
Christopher Rankin Photo 4

Christopher Rankin

Location:
Washington D.C. Metro Area
Industry:
Public Policy
Christopher Rankin Photo 5

Executive Protection Specialist , Advances, Advisor

Location:
Washington D.C. Metro Area
Industry:
Security and Investigations

Business Records

Name / TitleCompany / ClassificationPhones & Addresses
Christopher Rankin
Manager
Arboretum and Nature Preserve, LLC PO Box 66475, Saint Petersburg, FL 33736
5361 Poyner Oaks Rd, Polk City, FL 33868
Christopher M. Rankin
Manager
Solar Pool Services LLC 465 48 Ave, Saint Petersburg, FL 33703

Publications

Us Patents

Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same

US Patent:
7355008, Apr 8, 2008
Filed:
Jan 9, 2004
Appl. No.:
10/754922
Inventors:
Jeffrey Stavenhagen - Brookville MD,
Sujata Vijh - Gaithersburg MD,
Christopher Rankin - Clarksburg MD,
Sergey Gorlatov - Gaithersburg MD,
Ling Huang - Gaithersburg MD,
Assignee:
Macrogenics, Inc. - Rockville MD
International Classification:
C07K 16/00
C12P 21/08
C07K 1/00
US Classification:
5303871, 5303873, 5303877
Abstract:
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same

US Patent:
7960512, Jun 14, 2011
Filed:
Jul 28, 2004
Appl. No.:
10/902588
Inventors:
Jeffrey Stavenhagen - Brookville MD,
Sujata Vijh - Gaithersburg MD,
Christopher Rankin - Clarksburg MD,
Sergey Gorlatov - Gaithersburg MD,
Ling Huang - Gaithersburg MD,
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
C12P 21/08
C07K 16/00
C07K 17/00
US Classification:
5303871, 5303873, 5303881
Abstract:
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same

US Patent:
8003774, Aug 23, 2011
Filed:
Jan 30, 2008
Appl. No.:
12/022762
Inventors:
Jeffrey B. Stavenhagen - Brookville MD,
Sujata Vijh - Gaithersburg MD,
Christopher Rankin - Clarksburg MD,
Sergey Gorlatov - Gaithersburg MD,
Ling Huang - Gaithersburg MD,
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
C07H 21/04
C12P 21/06
C12N 15/09
C12N 1/20
C12N 5/00
C12N 5/16
C12N 15/00
US Classification:
536 2353, 435 691, 435 696, 435440, 435455, 435325, 435326, 435328, 435330, 435331, 4352523, 4353201
Abstract:
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same

US Patent:
8192737, Jun 5, 2012
Filed:
Jan 30, 2008
Appl. No.:
12/022772
Inventors:
Jeffrey B. Stavenhagen - Brookville MD,
Sujata Vijh - Gaithersburg MD,
Christopher Rankin - Clarksburg MD,
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
A61K 39/395
C07K 16/00
US Classification:
4241301, 4241321, 4241331, 4241381, 4241411
Abstract:
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same

US Patent:
8217147, Jul 10, 2012
Filed:
Aug 10, 2006
Appl. No.:
11/502820
Inventors:
Jeffrey Stavenhagen - Brookville MD,
Sergey Gorlatov - Gaithersburg MD,
Christopher Rankin - Clarksburg MD,
Nadine Tuaillon - Gaithersburg PA,
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
C07K 16/00
C12P 21/08
C07H 21/04
C12Q 1/68
C12N 15/00
C12N 5/16
C07K 17/00
US Classification:
5303871, 5303873, 5303881, 435 6, 4353201, 435326, 536 2353
Abstract:
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same

US Patent:
8445645, May 21, 2013
Filed:
Jun 10, 2011
Appl. No.:
13/158169
Inventors:
Jeffrey Stavenhagen - Brookville MD,
Sujata Vijh - Gaithersburg MD,
Christopher Rankin - Clarksburg MD,
Sergey Gorlatov - Gaithersburg MD,
Ling Huang - Gaithersburg MD,
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
C07K 16/00
C12P 21/08
A61K 39/395
A61K 39/40
US Classification:
5303871, 5303873, 5303881, 53038822, 5303887, 4241301, 4241331, 4241341, 4241411, 4241441, 4241521, 4241531
Abstract:
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Fcgamma-Riib-Specific Antibodies And Methods Of Use Thereof

US Patent:
2005026, Nov 24, 2005
Filed:
Apr 15, 2005
Appl. No.:
11/108135
Inventors:
Scott Koenig - Rockville MD,
Maria Veri - Denwood MD,
Nadine Tuaillon - Gettysburg PA,
Ezio Bonvini - Rockville MD,
Jeffrey Stavenhagen - Brookville MD,
Christopher Rankin - Clarksburg MD,
International Classification:
A61K039/395
C07K016/46
US Classification:
424178100, 530391100
Abstract:
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same

US Patent:
2008011, May 15, 2008
Filed:
Oct 9, 2007
Appl. No.:
11/869410
Inventors:
Jeffrey B. Stavenhagen - Brookville MD,
Sergey Gorlatov - Gaithersburg MD,
Christopher Rankin - Clarksburg MD,
Nadine Tuaillon - Gettysburg PA,
Assignee:
MACROGENICS, INC. - Rockville MD
International Classification:
A61K 39/395
C07H 21/04
C12P 21/06
C12N 5/06
C07K 16/30
US Classification:
4241551, 435 691, 435326, 536 2353, 5303888
Abstract:
The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease. The methods of the invention are also of use in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

All data offered is derived from public sources. We do not verify or evaluate each piece of data, and makes no warranties or guarantees about any of the information offered. We do not possess or have access to secure or private financial information. People Background Check is not a credit reporting agency and does not offer consumer reports. None of the information offered by People Background Check is to be considered for purposes of determining any entity or person's eligibility for credit, insurance, employment, housing, or for any other purposes covered under the FCRA.